- Home
- XERS vs KODK Comparison
XERS vs KODK Comparison
Compare XERS & KODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | KODK |
|---|---|---|
| Founded | 2005 | 1880 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | XERS | KODK |
|---|---|---|
| Price | $6.16 | $13.50 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $10.83 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $49,590,000.00 | ★ $4,114,000,000.00 |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.26 | $4.94 |
| 52 Week High | $10.08 | $14.29 |
Technical Indicators
Market Signals| Indicator | XERS | KODK |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 71.64 |
| Support Level | $5.79 | $6.33 |
| Resistance Level | $6.41 | N/A |
| Average True Range (ATR) | 0.20 | 0.75 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 57.74 | 70.45 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About KODK Eastman Kodak Company
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.